Search

everythinglearnresearchcommunity

for

Search:↓

The treatment showed promising hair regrowth in advanced-stage hair loss.

Hyperbaric oxygen therapy shows promise for multiple sclerosis, but skepticism and funding issues limit tech use in clinics, and outdated single-drug cancer treatments may cause unnecessary side effects.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.

An 80-year-old man grew extra hair on his forearms after starting Alzheimer's medication rivastigmine.

Patients with non-small-cell lung cancer need significant survival gains to accept severe side effects.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Raman spectroscopy is promising for measuring and enhancing drug delivery in alopecia treatments.

Finasteride safety data in trials may be underreported or misrepresented.

Case-only trees and random forests improve predictions of treatment effects in clinical trials.

Extracellular vesicles are important for disease treatment and monitoring.

Low-level laser therapy did not reduce licking or improve lesions in dogs with ALD but did increase hair growth.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Clinical trials for alopecia areata need better inclusion and retention of patients of color.

The Hair660™ light therapy device effectively and safely improves hair density in people with androgenetic alopecia.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Countries with stricter cultures had fewer COVID-19 cases and deaths, paranoia is linked to false memories, psychosocial intervention works as well with or without antipsychotic drugs for young people with psychosis, smartphones can detect changes in behavior indicating illness relapse, and recruitment agents show regional and gender biases.

CTP-543 is generally safe for treating alopecia areata.

Practitioners treating hair loss need better education and resources to overcome challenges like commercial bias and ethical dilemmas.

Baricitinib was effective in treating alopecia areata in two major trials.

A specific gene mutation is linked to a hereditary form of dystonia that responds well to certain medications.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

The EMG-to-force model accurately predicts hip muscle forces during walking.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.

Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.